Life Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 123599 - 123599
Published: April 1, 2025
Language: Английский
Human Cell, Journal Year: 2025, Volume and Issue: 38(3)
Published: April 9, 2025
Language: Английский
Citations
0
Clinical and Experimental Medicine, Journal Year: 2025, Volume and Issue: 25(1)
Published: April 24, 2025
Language: Английский
Citations
0
Cancers, Journal Year: 2025, Volume and Issue: 17(6), P. 927 - 927
Published: March 8, 2025
Introduction: Liquid biopsies provide a less-invasive option to tissue for the early diagnosis, prognosis, and tailored therapy of colorectal cancer (CRC). CRC is major cause cancer-related death, identification essential improving patient outcomes. Review: Conventional diagnostic techniques, including colonoscopy biopsy, may be enhanced by liquid that examine circulating tumor cells (CTCs), DNA (ctDNA), extracellular vesicles (EVs), other indicators present in body fluids. These markers significant insights into biology, heterogeneity, therapeutic response. CTCs detected early-stage have prognostic significance disease recurrence survival, while ctDNA investigation uncover genetic mutations, epigenetic alterations, development. The minimal residual (MRD) postsurgery correlates with an elevated risk unfavorable underscoring its use assessing treatment effectiveness. Furthermore, non-coding RNAs (ncRNAs) contained inside EVs potential prospective biomarkers targets, facilitating diagnosis assessment. Notwithstanding biopsies, obstacles persist assay standardization, sensitivity enhancement, management heterogeneity. Additional extensive research required determine their function clinical practice. Conclusion: Overall, serve as instrument real-time monitoring, evaluating responses, directing individualized strategies patients.
Language: Английский
Citations
0
Life Sciences, Journal Year: 2025, Volume and Issue: unknown, P. 123599 - 123599
Published: April 1, 2025
Language: Английский
Citations
0